DK2280734T3 - Faktor-ix-konjugater med forlængede halveringstider - Google Patents

Faktor-ix-konjugater med forlængede halveringstider

Info

Publication number
DK2280734T3
DK2280734T3 DK09734192.9T DK09734192T DK2280734T3 DK 2280734 T3 DK2280734 T3 DK 2280734T3 DK 09734192 T DK09734192 T DK 09734192T DK 2280734 T3 DK2280734 T3 DK 2280734T3
Authority
DK
Denmark
Prior art keywords
conjugates
factor
half times
extended half
extended
Prior art date
Application number
DK09734192.9T
Other languages
Danish (da)
English (en)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Application granted granted Critical
Publication of DK2280734T3 publication Critical patent/DK2280734T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK09734192.9T 2008-04-24 2009-04-24 Faktor-ix-konjugater med forlængede halveringstider DK2280734T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4754408P 2008-04-24 2008-04-24
PCT/IB2009/005763 WO2009130602A2 (en) 2008-04-24 2009-04-24 Factor ix conjugates with extended half-lives

Publications (1)

Publication Number Publication Date
DK2280734T3 true DK2280734T3 (da) 2014-05-26

Family

ID=41171051

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09734192.9T DK2280734T3 (da) 2008-04-24 2009-04-24 Faktor-ix-konjugater med forlængede halveringstider

Country Status (22)

Country Link
US (1) US20110183906A1 (https=)
EP (1) EP2280734B1 (https=)
JP (1) JP2011519833A (https=)
KR (1) KR20110016440A (https=)
CN (1) CN102046205A (https=)
AU (1) AU2009239641B2 (https=)
BR (1) BRPI0911350A2 (https=)
CA (1) CA2722169A1 (https=)
CO (1) CO6300965A2 (https=)
CR (1) CR11763A (https=)
DK (1) DK2280734T3 (https=)
EC (1) ECSP10010632A (https=)
ES (1) ES2466340T3 (https=)
IL (1) IL208908A0 (https=)
MX (1) MX2010011672A (https=)
MY (1) MY158228A (https=)
NI (1) NI201000177A (https=)
NZ (1) NZ588854A (https=)
RU (1) RU2496521C2 (https=)
UA (1) UA101497C2 (https=)
WO (1) WO2009130602A2 (https=)
ZA (1) ZA201007559B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
CN102497884A (zh) 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
KR101912335B1 (ko) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN106110311A (zh) 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR20120061898A (ko) * 2009-08-20 2012-06-13 체에스엘 베링 게엠베하 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
UA126265C2 (uk) * 2010-07-09 2022-09-14 Байовератів Терапьютікс Інк. Поліпептид фактора іх і спосіб його застосування
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
EP3808378A1 (en) * 2011-05-27 2021-04-21 Baxalta GmbH Therapeutic proteins with increased half-life and methods of preparing same
MY190257A (en) * 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
MX2014015682A (es) * 2012-06-19 2015-07-23 Polytherics Ltd Proceso novedoso para preparacion de conjugados de anticuerpo y conjugados de anticuerpo novedosos.
TWI750197B (zh) 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Fix多肽的應用
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
EA202092926A3 (ru) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
GB2564389A (en) 2017-07-04 2019-01-16 Green Running Ltd A system and method for utility management

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
DE60138364D1 (de) * 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1578841B2 (en) * 2002-12-31 2016-10-12 Nektar Therapeutics AL, Corporation Maleamic acid polymer derivatives and their bioconjugates
WO2004060965A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP1581582B2 (en) * 2003-01-06 2017-06-07 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
WO2005033140A1 (ja) * 2003-09-30 2005-04-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 高純度血液凝固ix因子調製物およびその精製方法
ATE466074T1 (de) 2003-10-14 2010-05-15 Baxter Int Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR101146160B1 (ko) * 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ix 부분의 접합체
EP1819829A1 (en) 2004-12-08 2007-08-22 ICOS Corporation Recombinant method for making multimeric proteins
ES2397530T3 (es) 2005-02-28 2013-03-07 Baxter International Inc. Coexpresión recombinante de la subunidad 1 de la epóxido reductasa de la vitamina K para mejorar la expresión de proteína dependiente de la vitamina K
AU2005329450A1 (en) 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active Vitamin K-dependent proteins
EP1891231A4 (en) * 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
KR20090013816A (ko) * 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
JP5737821B2 (ja) * 2006-08-17 2015-06-17 一夫 大橋 血友病b治療剤及びその製造方法

Also Published As

Publication number Publication date
CR11763A (es) 2011-04-26
ES2466340T3 (es) 2014-06-10
KR20110016440A (ko) 2011-02-17
RU2010147813A (ru) 2012-05-27
CA2722169A1 (en) 2009-10-29
US20110183906A1 (en) 2011-07-28
IL208908A0 (en) 2011-01-31
AU2009239641A1 (en) 2009-10-29
BRPI0911350A2 (pt) 2017-12-05
EP2280734B1 (en) 2014-02-26
MX2010011672A (es) 2011-03-02
ZA201007559B (en) 2012-01-25
WO2009130602A2 (en) 2009-10-29
NI201000177A (es) 2011-08-29
AU2009239641B2 (en) 2013-11-07
CO6300965A2 (es) 2011-07-21
HK1151986A1 (en) 2012-02-17
EP2280734A2 (en) 2011-02-09
ECSP10010632A (es) 2011-02-28
UA101497C2 (ru) 2013-04-10
WO2009130602A3 (en) 2010-02-11
RU2496521C2 (ru) 2013-10-27
MY158228A (en) 2016-09-15
NZ588854A (en) 2011-12-22
WO2009130602A9 (en) 2010-04-22
CN102046205A (zh) 2011-05-04
JP2011519833A (ja) 2011-07-14

Similar Documents

Publication Publication Date Title
FIC20240020I1 (fi) Atetsolitsumabi
DK2280734T3 (da) Faktor-ix-konjugater med forlængede halveringstider
DK2308877T3 (da) Imidazopyridin-2-on-derivater
DK2370462T3 (da) Glucagon-analoger
DK2342317T3 (da) Hængende-dråbe-plade
DE602009000234D1 (de) msignals
BRPI0907376A2 (pt) Fotobiorretador
DK3444343T3 (da) Polypeptider
BRPI0918823A2 (pt) beta-glicosidases modificadas com estabilidades aperfeicoada
DK2373293T3 (da) Sammensætninger med reduceret dimerdannelse
EP2329802A4 (en) EMBEDDED AUDIOPHONE
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2336132T3 (da) Morpholinpurinderivat
DK2335031T3 (da) In-line-måler
DK2275414T3 (da) Cyclopentylacrylamidderivat
DK2379557T3 (da) Aminopyrazol-forbindelse
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
EP2248964A4 (en) DRILLING / TERMINAL DEVICE
BRPI0907522A2 (pt) biarlamidas
DE112009000183A5 (de) Sicherheitsvorreiber
ATE534634T1 (de) 2-phenyl-4-cyclopropyl-pyrimidinderivate
BRPI0909634A2 (pt) 2-aminoquinolinas
DE602009000862D1 (de) Gehwagenbremse
DK2380892T3 (da) Imidazothiazolderivat med prolinringstruktur
DE112009001946A5 (de) Mobelauszugsführung